Today

Agents

Chat

Arena

Discover

More

App

Agilent wins EU approval for PD-L1 IHC 22C3 test in ovarian cancer patients - A News | Rallies

Agilent wins EU approval for PD-L1 IHC 22C3 test in ovarian cancer patients

A•2026-07-23

EU certification for companion diagnostic

Agilent won EU certification for its PD-L1 IHC 22C3 pharmDx (SK006) companion diagnostic in certain ovarian-related carcinomas.
The label expansion supports patient selection for Merck’s KEYTRUDA (pembrolizumab) in line with approved EU use.

Related News

Apple Maps integrates into Ford UEV platform under new automotive SDK deal

AAPL•2026-07-23

Merlin signs MoU with Israel Aerospace Industries on AI autonomy for cargo aircraft

MRLN•2026-07-23

TotalEnergies to exit Arctic LNG 2 plant in Russia, CEO says

•

2026-07-23

Sagtec Global expects first-half 2026 revenue about US$11.23 million, gross profit about US$3.12 million

SAGT•2026-07-23

NVR Q2 FY26 net income drops 29% to $236.5 million; revenue falls 10% to $2.33 billion

NVR•2026-07-23